Clinical Trial Update: Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer [EARLY_Phase 1]

View source ↗

Summary

An early-phase pharmacodynamic study of radium-223 in men with bone-metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Duke University | Conditions: Bone Metastatic Castration-Resistant Prostate Cancer | EARLY_Phase 1 | Status: COMPLETED